What happened with COLL today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Collegium Pharmaceutical’s largest business is pain medicine: Belbuca, Xtampza ER and Nucynta IR and ER together generate most of its revenue. It also sells Jornay PM for attention-deficit/hyperactivity disorder (ADHD) and Symproic for constipation caused by opioid treatment. Its dedicated pain and ADHD sales teams reach prescribing physicians, while wholesalers buy the medicines and distribute them to pharmacies and healthcare organizations.
A small group of large wholesalers handles much of its product shipments. Demand depends on physicians prescribing its medicines and government and private insurers covering them. Coverage terms, discounts and rebates affect how much Collegium earns from each sale.
Collegium outsources manufacturing. Patheon is the sole manufacturer of Xtampza ER and Nucynta ER, and the company obtains active ingredients from sole or limited suppliers. Its opioid pain medicines and Jornay PM are controlled substances, so manufacturing and distribution require regulatory registrations and compliance with handling rules. U.S. Drug Enforcement Administration quotas also limit the quantities of key ingredients available for Xtampza ER, Nucynta and Jornay PM.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Collegium’s results depend on pain and ADHD prescriptions, insurance coverage and generic substitution, with Purdue Pharma an important opioid rival to watch outside this list.
Supernus Pharmaceuticals, Inc.’s Qelbree competes with Collegium’s Jornay PM for ADHD prescriptions and insurance coverage, despite belonging to a different drug class. Watch Qelbree’s coverage and sales for signs of the competition facing Jornay PM.
AYTU BioPharma, Inc. competes for the same branded extended-release ADHD prescriptions as Collegium: its Adzenys XR-ODT and Cotempla XR-ODT are rivals to Jornay PM.
Amneal Pharmaceuticals, Inc. puts price and insurance-coverage pressure on Collegium’s branded pain and ADHD medicines by selling competing generic opioids and methylphenidate.
Vertex Pharmaceuticals’ suzetrigine competes with Collegium’s Nucynta IR by offering adults with moderate-to-severe acute pain a non-opioid treatment. Watch suzetrigine’s sales for signs of competition in acute-pain prescriptions.
Collegium depends on Thermo Fisher Scientific, Inc.’s Patheon to manufacture its pain medicines Xtampza ER and Nucynta ER; Patheon is the sole manufacturer of both. Any production interruption matters for those sales, because qualifying a replacement would take time and cost more.
Thermo Fisher Scientific, Inc. earningsTMO
Thermo Fisher Scientific’s report will show whether Patheon is sustaining production of the two pain medicines it makes for Collegium, Xtampza ER and Nucynta ER.
Look for what Thermo Fisher says about Patheon’s manufacturing operations and continuity, alongside Collegium’s supply of the two medicines. Stable operations would support sales through Collegium’s sole manufacturer; signs of disruption would put supply and sales at risk, while qualifying another manufacturer would take time and money.
Fed Interest Rate Decision
Collegium’s $580 million floating-rate term loan costs more when policy rates and the SOFR benchmark rise, leaving less cash for its medicines business and other needs.
Expected4.0%Last release4.0%
If it comes in above expectations
Higher rates can lift the loan’s interest expense, leaving less cash for Collegium to commercialize Jornay PM, Belbuca, Xtampza ER and its other medicines or to meet debt payments.
If it comes in below expectations
Lower rates can ease the loan’s interest expense, leaving Collegium more cash for its medicines business and debt payments.
Collegium Pharmaceutical, Inc. earningsThis company
Collegium Pharmaceutical’s report will show whether sales of its six medicines are still growing and turning into operating profit.
Read net product revenue by medicine alongside product costs, especially whether Jornay PM still accounts for most of the growth and whether gross profit—the amount left after product costs—keeps pace. Growth across several medicines with rising gross profit would point to broader demand translating into profit; growth concentrated in Jornay PM, or costs absorbing more revenue, would leave the rest of the portfolio and profit conversion as concerns.
